Cat.#: BBM-3C-020
| Description | Bovine Collagen Type I and III, 10 mg from Ace Therapeutics is purified from calf skin. Type I collagen is the most abundant collagen and is found in connective tissues including tendons, ligaments, dermis, and blood vessels. Type III collagen is the second most abundant collagen in tissues and is found most commonly in tissues exhibiting elastic properties such as skin, lungs, intestinal walls, and walls of blood vessels, which resembles other fibrillar collagens in structure and function. |
| Source | Bovine (calf) skin |
| Size | 10 mg/ vial |
| Form | Lyophilized, salt free, |
| Purity | Bovine collagen type I 45%. Bovine collagen type III 45%. Bovine collagen other type <10%. Non-collagen proteins <0.5%. |
| Sterility | Passed sterility test for bacteria and fungi. |
| Storage | Storage (2 years) at -20°C or lower. |
| Shipping | Dry ice |
| Aplications | Used for coating material for cell culture studies. May not be suitable for 3-D gel formation. |
| Cat.# | Name | Description | Price |
|---|---|---|---|
| BBM-3C-065 | Collagen, Type I, from Mouse Tail |
The mouse tail collagen I provided by Ace Therapeutics is prepared according to the Birkedal-Hansen method through acetic acid extraction, sodium chloride precipitation, and disodium hydrogen phosphate precipitation. This product is derived from a mouse tail, dissolved in 0.02M HAc solution, and the purity is greater than 90% as determined by SDS-PAGE, and it is sterile.
|
inquiry |
| BBM-3C-046 | Rat Tail Collagen I, 3 mg/mL |
Rat Tail Collagen I, 3 mg/mL from Ace Therapeutics is derived from rat tail, which can be prepared as a clear gel to provide a 3D matrix or surface coating on tissue culture plates as a substrate for culturing primary cells such as keratinocytes and hepatocytes.
|
inquiry |
| BBM-3C-032 | Human Collagen Type II, 0.1 mg |
Human Collagen Type II, 0.1 mg from Ace Therapeutics is purified from human cartilage.
|
inquiry |
| BBM-3C-060 | Collagens Type I-P |
Collagens Type I-P is pepsin-solubilized Type-I collagen derived from pig tendon. The product has low viscosity, making it easy to handle and form gels.
|
inquiry |
| BBM-3C-030 | Bovine Collagen Type V (Atelocollagen), 1 mg |
Bovine Collagen Type V (Atelocollagen), 1 mg from Ace Therapeutics is purified from bovine placenta.
|
inquiry |
| BBM-3C-064 | Collagen, Type I, from Rat Tail |
The rat tail collagen I provided by Ace Therapeutics is prepared according to the Birkedal-Hansen method through acetic acid extraction, sodium chloride precipitation, and disodium hydrogen phosphate precipitation. This product is derived from a rat tail, dissolved in 0.02M HAc solution, and the purity is greater than 90% as determined by SDS-PAGE, and it is sterile.
|
inquiry |
| BBM-3C-029 | Bovine Collagen Type III, 10 mg |
Bovine Collagen Type III, 10 mg from Ace Therapeutics is purified from bovine (calf ) skin.
Type III collagen is the second most abundant collagen in tissues and is found most commonly in tissues exhibiting elastic properties such as skin, lungs, intestinal walls, and walls of blood vessels, which resembles other fibrillar collagens in structure and function.
|
inquiry |
| BBM-3C-035 | Human Collagen Type V, 0.1mg |
Human Collagen Type V, 0.1mg from Ace Therapeutics is purified from human placenta.
Type V collagen, a fibrillar collagen, is critical for the fibrillation of types I and III collagen, contributing to optimal fibril formation and tissue quality.
|
inquiry |
| BBM-3C-071 | Rat Collagen I, Lower Viscosity |
Rat Collagen I, Low Viscosity from Ace Therapeutics is a purified stromal extracellular matrix protein from rat tail tendons. This product is provided at a standard concentration that is lower in viscosity, making it easier to work with.
|
inquiry |
| BBM-3C-056 | Porcine Gelatine |
Porcine Gelatine from Ace Therapeutics is a purified gelatin matrix from porcine tissue. The product can enhance the adsorption of various normal cells and transfected cells.
|
inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.